Gautam Exim
- Market cap
- ₹ 54 Cr.
- P/E
- 191.5x
- P/B
- 4.4x
- 52-week range
- 17.08 – 46.19
- ROE
- 2%
- ROCE
- 5.6%
- Dividend yield
- 0%
- Debt / equity
- 0.01
- Sector
- Commercial Services & Supplies
- Industry
- Trading & Distributors
- Listed on
- BSE SME
About
Gautam Exim Limited is an India-based trader and importer of imported wastepaper and indigenous wastepaper, chemicals and finished paper. The Company is engaged in importing of wastepaper, pulp, and specialty chemicals, provides import trading, import aggregation. The Company provides import facilitation services of industrial raw material, stores, spares to paper mills, chemical units, and other manufacturing units. Import of these goods is done from United States, United Kingdom, Europe, Middle East, and Australia. It is an exporter of kraft paper rolls, fluting media and liner boards, kraft paper pulp, writing and printing paper, newsprint, and paper boards for tubes and cones. The Company acts as collection agent in India for overseas suppliers for their exports into India. The Company also undertakes professional study for structuring the financing model suitable for the clients.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Trading & Distributors: 197 companies →Gautam Exim against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)191.5 against a typical 28.5: pricier than most peers (1st = cheapest).163rd of 186
- Sales growth−82.9% against a typical −2.4% from a year earlier.123rd of 143
- Profit growth−87.5% against a typical −13.1% from a year earlier.92nd of 124
- Share price, 3 months−46.8% against a typical −4.9%.167th of 169
- Size₹ 53.6 Cr. market value against a typical ₹ 26.8 Cr. (1st = largest).68th of 183
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Mar 2020 | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 141 | 105 | 146 | 226 | 153 | 141 | 140 | 105 | 64 | 21 | 15 | 18 |
| Expenses | 140 | 103 | 144 | 225 | 152 | 140 | 139 | 104 | 64 | 21 | 15 | 18 |
| Operating Profit | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| OPM % | 1.2% | 1.5% | 1.5% | 0.8% | 1% | 0.8% | 0.7% | 0.6% | 0.7% | 1.3% | 2% | 2% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −0 | 0 |
| Profit before tax | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | −0 | 0 | 0 | 0 |
| Tax % | 17.4% | 28.6% | 22% | 30.8% | 23.6% | 28% | 24% | 27.3% | 0% | 20% | 18.2% | 33.3% |
| Net Profit | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | −0 | 0 | 0 | 0 |
| EPS in Rs | 0.08 | 0.09 | 0.18 | 0.18 | 0.22 | 0.07 | 0.08 | 0.07 | −0.01 | 0.02 | 0.04 | 0.01 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- −21%
- 5 Years
- −35%
- 3 Years
- −53%
- TTM
- −18%
- 10 Years
- −10%
- 5 Years
- −20%
- 3 Years
- −16%
- TTM
- 69%
- 10 Years
- —
- 5 Years
- 46%
- 3 Years
- 37%
- TTM
- —
- 10 Years
- 6%
- 5 Years
- 3%
- 3 Years
- 1%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Gautam Exim | ₹ 17.08 | ₹ 54 Cr. | 191.5x | 4.4x | 2% | — |
| Bajaj Finance | ₹ 927.00 | ₹ 5,77,146 Cr. | 22.7x | 5.2x | — | 24.2% |
| Shriram Finance | ₹ 867.00 | ₹ 2,04,004 Cr. | 12.4x | 2.6x | — | 22.8% |
| Jio Financial Services | ₹ 205.00 | ₹ 1,35,364 Cr. | 83.8x | 1x | 1.3% | 35.1% |
| Tata Capital | ₹ 307.05 | ₹ 1,30,358 Cr. | 26.5x | 2.9x | — | 17.2% |
| Power Finance Corporation | ₹ 316.00 | ₹ 1,04,283 Cr. | 4.4x | 0.8x | — | 29.1% |
Management
- Raj Kumar Agrawal
- Chief Financial Officer, Managing Director, Additional Executive Director
- Balasubramanian Raman
- Additional Whole-time Director
Prices are delayed and for information only. Nothing on this page is investment advice.